Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers

Chemotherapy

Volumn 45, Issue 6, 1999, Pages 496-503

  Allen, Ann ^a   Vousden, Marika ^b   Lewis, Anastasia ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Clinical Pharmacology Unit   (United Kingdom)

Author keywords

Drug interactions; Fluoroquinolones; Gemifloxacin; Omeprazole; Pharmacokinetics

Indexed keywords

GEMIFLOXACIN; OMEPRAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0032737112     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007244     Document Type: Article

References (24)

1. Lode M, Schaberg T, Mauch H: Management of community-acquired pneumonia. Curr Opin Infect Dis 1991;9:367-371.
2. Baquero F, Barrett YF, Courvalin P, Morrissey I, Piddock L, Novick WY: Epidemiology and mechanisms of resistance among respiratory tract pathogens. Clin Microbiol Infect 1997;4(suppl 12):S19-S26.
3. Moore T, Niconovich N, Coleman K: SB-265805 (LB20304a): In-vitro antibacterial activity against the common respiratory tract pathogens Streptococcus pneumoniae, Haemophilia influenzae and Moraxella catarrhalis. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998, San Diego, CA, USA. Poster F-098.
4. Critchley IA, Broskey J, Coleman K: SB-265805 (LB20304a): In-vitro activity, intracellular accumulation and killing of Legionella pneumophila in human macrophages. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998, San Diego, CA, USA. Poster F-100.
5. Allen A, Bygate E, Teillol-Foo M, Oliver S, Johnson M, Ward C: Pharmacokinetics and tolerability of gemifloxacin after administration of single oral doses to healthy volunteers; in: Abstracts from the 21st International Congress of Chemotherapy, Birmingham, UK. J Antimicrob Chemother 1999;44(suppl A): 137:Poster 440.
6. Allen A, Bygate E, Teillol-Foo M, Oliver S, Johnson M, Ward C: Multiple-dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers; in: Abstracts from the 21st International Congress of Chemotherapy, Birmingham, UK. J Antimicrob Chemother 1999;44(suppl A):133:Poster 418.
7. Jaehde U, Sörgel F, Koch HU, Stephan U, Gottschalk B, Schunack W: Gastrointestinal and hepatic drug interactions with pefloxacin, a new quinolone. Clin Pharmacol Ther 1987;41:166.
8. Höffken G, Lode H, Wiley R, Glatzel TD, Sievers D, Olschewski T, Borner K, Koeppe T: Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev Infect Dis 1988;10(suppl 1):S138-S139.
9. Grasela TH, Schentag JJ, Sedman AJ, Wilton JH, Thomas DJ, Schultz RW, Lebsack ME, Kinkel AW: Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother 1989;33:615-617.
10. Lomaestro BM, Bailie GR: Quinolone-cation interactions: a review. Ann Pharmacother 1991;25:1249-1258.
11. Granneman GR, Stephan U, Birner B, Sörgel F, Mukherjee D: Effect of antacid medication on the pharmacokinetics of temafloxacin. Clin Pharmacokinet 1992;22(suppl 1): 83-89.
12. Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J: Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother 1997;39(suppl B):93-97.
13. Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ: Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 1989;33:99-102.
14. Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yashke CC: Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother 1990;34: 931-933.
15. Nix DE, Watson WA, Lener ME, Frost RW, Krol G, Goldstein H, Lettieri J, Schentag JJ: Effects of aluminium and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700-705.
16. Regårdh C-G: Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 1986; 118(suppl):99-104.
17. Prichard PJ, Yeomans NK, Mihaly GW, Jones DB, Buckle PJ, Smallwood RA, Louis WJ: Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985;88:64-69.
18. Cederberg C, Andersson T, Skånberg I: Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989;166(suppl):33-40.
19. Clissold SP, Campoli-Richards DM: Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986;32:15-47 (erratum: Drugs 1986;32:383).
20. Clissold SP, Campoli-Richards DM: Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986;32:15-47 (erratum: Drugs 1986;32:383).
21. Jensen JC, Gugler R: Inhibition of human liver cytochrome P-450 by omeprazole. Br J Clin Pharmacol 1986;21:328-330.
22. Stuht H, Lode H, Koeppe P, Rost KL, Schaberg T: Interaction study of lomefloxacin and ciprotloxacin with omeprazole and comparative pharmacokinetics. Antimicrob Agents Chemother 1995;39:1045-1049.
23. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L: Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983;24: 270-276.
24. Chiou WL: Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978;6:539-547.